Skip to main content
Back
PTGX logo

Protagonist Therapeutics, Inc.

Data quality: 100%
PTGX
NASDAQ Healthcare Biotechnology
$104.31
▲ $3.92 (3.90%)
Mkt Cap: 6.66B
Day Range
$97.16 $104.98
52-Week Range
$39.60 $105.69
Volume
798,945
50D / 200D Avg
$87.11 / $72.76
Prev Close
$100.39

Quick Summary

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (631 peers)

Metric Stock Sector Median
P/E -51.1 0.2
P/B 10.8 3.0
ROE % -20.2 3.6
Net Margin % -282.8 3.8
Rev Growth 5Y % 13.9 9.9
D/E 0.0 0.2

Analyst Price Target

Hold
$113.60 +8.9%
Low: $108.00 High: $121.00
Forward P/E
32.30
Forward EPS
$3.23
EPS Growth (est.)
+0.0%
Est. Revenue
441.40M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $4.65
-$0.61 – $9.06
 601.88M 2
FY2029 $2.57
-$0.34 – $5.01
 419.23M 4
FY2028 $1.56
-$7.56 – $10.54
 303.31M 6

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-25 -$0.57 -$0.69 -21.7%
2025-11-06 -$0.59 -$0.62 -5.1%
2025-08-06 -$0.53 -$0.55 -3.8%
2025-05-06 -$0.50 -$0.19 +62.0%
2025-02-21 $0.06 $1.98 +3200.0%
2024-11-07 -$0.59 -$0.54 +8.5%
2024-08-06 -$0.50 -$0.50 0.0%
2024-05-07 $1.19 $3.26 +173.9%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Key Takeaways

Revenue grew 13.88% annually over 5 years — strong growth
Earnings declined -147.29% over the past year
Debt/Equity of 0.02 — conservative balance sheet
Generating 56.08M in free cash flow
PEG of 0.29 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 103.29%

Growth

Revenue Growth (5Y)
13.88%
Revenue (1Y)-89.41%
Earnings (1Y)-147.29%
FCF Growth (3Y)N/A

Quality

Return on Equity
-20.18%
ROIC-18.97%
Net Margin-282.83%
Op. Margin-343.63%

Safety

Debt / Equity
0.02
Current Ratio12.71
Interest Coverage0.00

Valuation

P/E Ratio
-51.14
Forward P/E32.30
P/B Ratio10.83
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -89.41% Revenue Growth (3Y) -12.43%
Earnings Growth (1Y) -147.29% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13.88% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 46.02M Net Income (TTM) -130.15M
ROE -20.18% ROA -19.43%
Gross Margin 97.34% Operating Margin -343.63%
Net Margin -282.83% Free Cash Flow (TTM) 56.08M
ROIC -18.97% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 12.71
Interest Coverage 0.00
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -51.14 Forward P/E 32.30
P/B Ratio 10.83 P/S Ratio 144.64
PEG Ratio 0.29 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 15.08 Fwd Earnings Yield 3.10%
FCF Yield 0.84%
Market Cap 6.66B Enterprise Value 6.54B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 46.02M 434.43M 60.00M 26.58M 27.36M
Net Income -130.15M 275.19M -78.96M -127.39M -125.55M
EPS (Diluted) -2.05 4.23 -1.39 -2.52 -2.65
Gross Profit 44.79M 434.43M 60.00M 26.58M 27.36M
Operating Income -158.13M 252.84M -93.65M -131.37M -125.85M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 669.89M 744.73M 357.95M 247.93M 347.70M
Total Liabilities 55.19M 69.43M 21.27M 32.32M 47.67M
Shareholders' Equity 614.71M 675.30M 336.68M 215.61M 300.02M
Total Debt 10.32M 10.87M 1.14M 3.66M 5.86M
Cash & Equivalents 128.39M 97.25M 186.73M 125.74M 123.67M
Current Assets 577.57M 591.64M 355.58M 243.08M 340.74M
Current Liabilities 45.44M 47.40M 21.27M 31.18M 44.02M